地塞米松植入剂（Ozurdex）联合康柏西普（Conbercept） ——治疗视网膜中央静脉阻塞继发黄斑水肿的临床研究
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i1.6680
Abstract
目的：评价地塞米松植入剂(Ozurdex)联合康柏西普(Conbercept)及各单药治疗视网膜中央静脉阻塞伴黄斑水肿(CRVO-ME)的临床疗效。方法：分析比较两型三组CRVO-ME的患者治疗后最佳矫正视力(BCVA)、黄斑中心凹厚度(CFT)、黄斑容积(MV)、视网膜平均厚度(CRT)、注射次数、眼内压(IOP)和并发症出现情况。结果：在6个月治疗后两型三组患者治疗后BCVA、MV和CFT及CRT均优于治疗前；联合组及Conbercept组治疗后BCVA、MV和CFT及CRT均优于Ozurdex组；IOP和CFT及CRT在缺血型与非缺血型患者中差异无统计学意义。结论：Ozurdex联合Conbercept治疗CRVO-ME,可以用相对较少的注射次数使患者在BCVA、MV、CFT和CRT方面得到改善,其治疗效果明显好于单纯应用Ozurdex或Conbercept。
Keywords
视网膜中央静脉阻塞；黄斑水肿；地塞米松植入剂；康柏西普
Funding
云南省教育厅科学研究基金项目, 项目编号：2022J0735。
Full Text
PDF - Viewed/Downloaded: 0 TimesIndexation
Download Index RecordReferences
[1] Khayat Meiaad,Williams Michael,Lois Noemi,Ischemic re tinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion.[J] .Surv Ophthalmol,2018,63:816-850.
[2] 邓玉梦,黄珍,叶娅,等.强反射点与视网膜分支静脉阻塞和中央静脉阻塞患者血脂水平和炎症指标的相关性[J].中华眼底病杂志,2021,37(2):115-121.
[3] .Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion[J]. Jpn J Ophthalmol,2011,55(3):256-263.
[4] 方丽英,黄宝宇,黄敏丽.Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效对比[J].眼科新进展,2021,41(3):231-235.
[5] Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized,shamcontrolled,multicenter study[J].Graefe's Arch Clin Exp Ophthalmol,2018,256(1):59-69.
[6] Gu X, Yu X, Song S, et al. Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chine se population[J]. Ophthalmic Res,2017,58(1):8-14.
[7] Chatziralli Irini,Theodossiadis George,Kabanarou Stam atina A et al. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study.[J].Graefes Arch Clin Exp Ophthalmol,2017,255:1899-1905.
[8] Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J,Li XY,Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlu- sion.Ophthalmology,2011,117(6):1134-1146.
[2] 邓玉梦,黄珍,叶娅,等.强反射点与视网膜分支静脉阻塞和中央静脉阻塞患者血脂水平和炎症指标的相关性[J].中华眼底病杂志,2021,37(2):115-121.
[3] .Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion[J]. Jpn J Ophthalmol,2011,55(3):256-263.
[4] 方丽英,黄宝宇,黄敏丽.Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效对比[J].眼科新进展,2021,41(3):231-235.
[5] Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized,shamcontrolled,multicenter study[J].Graefe's Arch Clin Exp Ophthalmol,2018,256(1):59-69.
[6] Gu X, Yu X, Song S, et al. Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chine se population[J]. Ophthalmic Res,2017,58(1):8-14.
[7] Chatziralli Irini,Theodossiadis George,Kabanarou Stam atina A et al. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study.[J].Graefes Arch Clin Exp Ophthalmol,2017,255:1899-1905.
[8] Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J,Li XY,Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlu- sion.Ophthalmology,2011,117(6):1134-1146.
Copyright © 2024 刘腾, 段直光
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License